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Comparison of Risk Stratification
Schemes to Predict Thromboembolism
in People With Nonvalvular Atrial Fibrillation
Margaret C. Fang, MD, MPH,* Alan S. Go, MD,*† Yuchiao Chang, PHD,‡ Leila Borowsky, MPH,‡
Niela K. Pomernacki, RD,† Daniel E. Singer, MD,‡ for the ATRIA Study Group
San Francisco and Oakland, California; and Boston, Massachusetts
Objectives We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF)–related thromboembo-
lism in a large community-based cohort.
Background Risk schemes can help target anticoagulant therapy for patients at highest risk for AF–related thromboembo-
lism. We tested the predictive ability of 5 risk schemes: the Atrial Fibrillation Investigators, Stroke Prevention in
Atrial Fibrillation, CHADS2 (Congestive heart failure, Hypertension, Age  75 years, Diabetes mellitus, and prior
Stroke or transient ischemic attack) index, Framingham score, and the 7th American College of Chest Physi-
cians Guidelines.
Methods We followed a cohort of 13,559 adults with AF for a median of 6.0 years. Among non-warfarin users, we identi-
fied incident thromboembolism (ischemic stroke or peripheral embolism) and risk factors from clinical data-
bases. Each scheme was divided into low, intermediate, and high predicted risk categories and applied to the
cohort. Annualized thromboembolism rates and c-statistics (to assess discrimination) were calculated for each
risk scheme.
Results We identified 685 validated thromboembolic events that occurred during 32,721 person-years off warfarin ther-
apy. The risk schemes had only fair discriminating ability, with c-statistics ranging from 0.56 to 0.62. The propor-
tion of patients assigned to individual risk categories varied widely across the schemes. The proportion catego-
rized as low risk ranged from 11.7% to 37.1% across schemes, and the proportion considered high risk ranged
from 16.4% to 80.4%.
Conclusions Current risk schemes have comparable, but only limited, overall ability to predict thromboembolism in persons
with AF. Recommendations for antithrombotic therapy may vary widely depending on which scheme is applied
for individual patients. Better risk stratification is crucially needed to improve selection of AF patients for antico-
agulant therapy. (J Am Coll Cardiol 2008;51:810–5) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.065t
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tonvalvular atrial fibrillation (AF) is a major risk factor for
hromboembolism, causing approximately 15% of the isch-
mic strokes in the U.S. (1). Anticoagulant therapy with
itamin K antagonists such as warfarin sodium can substan-
rom the *Department of Medicine, University of California at San Francisco, San
rancisco, California; †Division of Research, Kaiser Permanente of Northern Cali-
ornia, Oakland, California; and the ‡Clinical Epidemiology Unit, Massachusetts
eneral Hospital, Boston, Massachusetts. This study was supported by Public Health
ervices research grant AG15478 from the National Institute on Aging, the Eliot B.
nd Edith C. Shoolman Fund of Massachusetts General Hospital (Boston, Massa-
husetts), a Hartford Geriatrics Health Outcomes Research Scholars Award from the
merican Geriatrics Society Foundation for Health in Aging (New York, New York),
nd a Paul B. Beeson Career Development Award in Aging from the National
nstitute on Aging (K23 AG28978).t
Manuscript received July 2, 2007; revised manuscript received September 11, 2007,
ccepted September 17, 2007.ially reduce the risk of AF–related thromboembolism, but
t the risk of incurring more hemorrhagic complications (2).
ccurate stratification of patients with AF by thromboem-
olism risk should ideally target the use of warfarin for
atients at highest risk of thromboembolism and reduce the
xposure of low-risk patients to the complications of war-
arin (3–5).
See page 816
Several prominent risk stratification schemes have been
eveloped to help distinguish those patients with AF who
re at high risk for ischemic stroke and other systemic
hromboembolism from those with a risk sufficiently low
hat anticoagulation might not be beneficial when consid-
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February 26, 2008:810–5 Risk Stratification for AFring the associated bleeding risks (2,6–9). Two schemes
ere developed from multivariable analyses of pooled data
rom randomized trial participants: the Atrial Fibrillation
nvestigators (AFI) and the Stroke Prevention in Atrial
ibrillation (SPAF) risk schemes (2,6). The CHADS2
Congestive heart failure, Hypertension, Age  75 years,
iabetes mellitus, and prior Stroke or transient ischemic
ttack) index, named for a combination of clinical risk
actors, was subsequently developed from an amalgamation
f the AFI and SPAF schemes and validated using data
rom a registry of hospitalized Medicare beneficiaries with
F (7). A risk score based on the Framingham Heart Study
ohort was developed to predict 5-year risk of stroke, but it
as yet to be validated in other community settings (8).
inally, a guideline from the 7th American College of Chest
hysicians Conference on Antithrombotic and Thrombo-
ytic Therapy (ACCP) was developed through expert opin-
on and review of the available evidence (9).
Although many of the clinical variables overlap among
he different risk schemes, there are differences in how
pecific variables are coded (e.g., age as a continuous variable
s opposed to a dichotomous variable), combined, and
eighted. Because these variations may lead to significant
ifferences in whether patients are categorized as being at
ow or high risk for thromboembolism, the choice of
uideline could potentially influence the recommendation of
arfarin for individual patients. We assessed the predictive
bility of these 5 risk stratification schemes when applied to
large, independent, community cohort of patients with
F.
ethods
he ATRIA (AnTicoagulation and Risk Factors In Atrial
ibrillation) study is a cohort of 13,559 adults with diag-
osed nonvalvular AF who received care within Kaiser
ermanente of Northern California, a large integrated
Risk Stratification Schemes Used to Predict Thromboembolism in
Table 1 5 Risk Stratification Schemes Used to Predict Thromb
Risk Scheme Low Risk
AFI Age 65 yrs and no risk factors Age 65 y
SPAF No risk factors History of
CHADS2† Score 0 Score 1 to
Framingham‡ Score 0 to 7 Score 8 to
7th ACCP Age 65 yrs and no other risk
factors
Age 65 to
The AFI, SPAF, CHADS2, and Framingham schemes were developed to predict atrial fibrillation–rel
hat assigns 1 point each for Congestive heart failure, Hypertension, Age 75 years or older, and Di
point system based on the following clinical factors: age (0 to 10 points), female gender (6 points)
schemic attack (6 points) (8).
ACCP  American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Thera
ypertension, Age 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack; SPAF  Sealth care delivery system. De-
ails of the cohort assembly have
een described previously
10,11). We identified patients
ith a diagnosis of AF between
uly 1, 1996, and December 31,
997, by searching automated
npatient, outpatient, and elec-
rocardiographic databases for
hysician-assigned International
lassification of Diseases-Ninth
evision-Clinical Modification
ICD-9-CM) diagnosis of AF
427.31). The cohort was fol-
owed up through September
003, a median follow-up of 6.0
ears (interquartile range 3.1 to
.7 years). To specifically address
onvalvular AF, we excluded pa-
ients with diagnoses of mitral
tenosis, documented valvular re-
air or replacement, transient post-operative AF, or con-
urrent hyperthyroidism. Warfarin exposure among patients
as determined from computerized records from pharmacy,
aboratory, and ambulatory visits using previously described
nd validated methods (10). The analyses for our study were
estricted to the 10,932 patients who had periods of time
hen they appeared not to be taking warfarin.
atient characteristics and risk stratification schemes for
hromboembolism. Each of the 5 risk stratification
chemes (Table 1) was constructed to assign patients to low,
ntermediate, and high thromboembolism risk categories,
onsistent with previous studies (3–5). The specific risk
actors included age, gender, history of ischemic stroke,
iagnosed heart failure, diagnosed hypertension, and diabe-
es mellitus. Data for individual medical conditions were
sons With Nonvalvular Atrial Fibrillation*
olism in Persons With Nonvalvular Atrial Fibrillation*
rmediate Risk High Risk
no other risk factors Prior ischemic stroke or transient ischemic
attack, history of hypertension, history of
diabetes mellitus
ension Prior stroke, women older than 75 yrs,
recent clinical heart failure, left
ventricular fractional shortening 25%
on echocardiography
Score 3 to 6
Score 16 to 31
and no other risk factors Prior ischemic stroke, age 75 yrs,
moderate to severe left ventricular
dysfunction, history of hypertension,
diabetes mellitus
hemic stroke, not ischemic stroke plus peripheral embolism. †The CHADS2 index is a point system
mellitus and 2 points for prior Stroke or transient ischemic attack (7). ‡The Framingham score is
ic blood pressure (0 to 4 points), diabetes mellitus (5 points), and prior ischemic stroke or transient
Abbreviations
and Acronyms
ACCP  American College
of Chest Physicians
Conference on
Antithrombotic and
Thrombolytic Therapy
AF  atrial fibrillation
AFI  Atrial Fibrillation
Investigators
CHADS2  Congestive
heart failure, Hypertension,
Age >75 years, Diabetes
mellitus, and prior Stroke
or transient ischemic
attack
CI  confidence interval
ICD-9-CM  International
Classification of Diseases-
Ninth Revision-Clinical
ModificationPer
oemb
Inte
rs and
hypert
2
15
75 yrs
ated isc
abetes
, systolpy guidelines (9); AFI  Atrial Fibrillation Investigators (2
troke Prevention in Atrial Fibrillation (6).); CHADS2  Congestive heart failure,
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Risk Stratification for AF February 26, 2008:810–5btained by searching for relevant ICD-9-CM codes in
utomated clinical databases during the 5 years before
nrollment and throughout follow-up. This search strategy
as been previously validated by comparing diagnoses to a
eview of a subset of patients’ medical records (10). The
TRIA cohort lacked data on individual patients’ systolic
lood pressure and left ventricular ejection fraction during
he study period, risk factors that were used in the SPAF
nd Framingham risk schemes (6,8). Instead, in our study,
clinical diagnosis of hypertension was substituted in place
f systolic blood pressure 160 mm Hg, and diagnosed
eart failure was substituted for left ventricular fractional
hortening 25%. The Framingham risk score used systolic
lood pressure as a risk factor, with 0 to 4 points assigned to
pecific ranges of systolic blood pressure. For our study, we
onsidered a diagnosis of hypertension in the ATRIA
ohort to equal 3 points on the Framingham score and then
onducted a sensitivity analysis of whether substituting
oints of 2 or 4 resulted in significantly different results.
dentification of thromboembolic events. We searched
he health plan electronic hospitalization and billing records
or primary discharge diagnoses referring to incident throm-
oembolic events, either ischemic stroke or other peripheral
mbolism. The validity of potential events was then adju-
icated by an outcomes committee of 3 physicians using a
ormal study protocol, with at least 2 physicians reviewing
he medical records for each potential event and a third
hysician reviewing cases in which the initial reviewers
isagreed. If there was no consensus on the validity of an
vent, an expert neurologist adjudicated the event. Valid
schemic strokes were defined as neurological deficits of
udden onset that persisted for more than 24 h and were not
xplained by other etiologies (e.g., trauma, infection, or
asculitis). Valid nonstroke peripheral emboli were defined
s emboli identified by radiographic imaging, intraoperative
xamination, or pathological findings, and without under-
ying atherosclerotic disease in the affected artery. We
xcluded outcome events that occurred during hospitaliza-
ion or as a complication from a diagnostic or interventional
rocedure. Because the goal of our study was to examine the
omparative utility of thromboembolic risk schemes for the
urpose of informing anticoagulant therapy decision mak-
ng, we only included thromboembolic events that occurred
ff warfarin therapy, determined by chart review.
tatistical analyses. Analyses were restricted to patients
ho were not taking warfarin therapy. Patients off warfarin
ere assigned to a low, intermediate, or high thromboem-
olism risk category for each risk scheme, and thromboem-
olism rates for each category were calculated as the number
f events per 100 person-years of follow-up off of warfarin
herapy. Because patients could accumulate additional clin-
cal risk factors over time, we updated each patient’s risk
actor status throughout follow-up using weighted logistic
egression models. Agreement between pairs of risk schemes
as tested using weighted kappa statistics. The discrimina-ory ability of each risk scheme as applied to the ATRIAohort was determined by calculating a c-statistic using
ogistic regression analysis. The c-statistic is analogous to
he area under the receiver-operating characteristic curve
nd represents the probability that the predicted risk is
igher for a patient with the outcome than without (12). A
-statistic of 1 indicates perfect discrimination, whereas a
alue of 0.5 indicates no discrimination (12,13). Because
ndividual subjects in the ATRIA cohort could have alter-
ating periods on and off warfarin, we weighted the analyses
or the time each patient was followed up off of warfarin
herapy. In addition, to address potential bias occurring
ecause of patients having different lengths of follow-up off
arfarin, we also calculated c-statistics for each risk scheme
hen applied to a subgroup of 5,588 patients who were not
n warfarin at baseline and who had continuous follow-up
ff warfarin therapy for a fixed period of 12 months.
All analyses were performed using SAS software, version
.1 (SAS Institute Inc., Cary, North Carolina). The insti-
utional review boards of the collaborating institutions
pproved the study, and the need for individual patient
ritten consent was waived because of the nature of the
tudy.
esults
total of 32,721 person-years of follow-up among patients
ith AF not taking warfarin were available for analysis. The
ean age of patients at baseline was 72 years, and 78.7%
ad at least 1 clinical risk factor for thromboembolism
Table 2). Forty percent of patients acquired at least 1
dditional clinical risk factor over the follow-up period. The
roportion of cohort member person-years categorized as
ow risk varied considerably across the risk schemes, ranging
rom 11.7% of the cohort using the 7th ACCP guidelines to
7.1% using the Framingham risk scheme (Table 3). There
as also substantial variation in the proportion of patients
onsidered high risk, which ranged from 16.4% of the
ohort using the Framingham risk scheme to as high as
0.4% using the 7th ACCP guidelines. Among patients
ho were not taking warfarin at baseline, agreement be-
ween schemes varied from poor (kappa of 0.21 for the
ramingham scheme vs. the 7th ACCP guidelines) to good
kappa of 0.71 for the AFI vs. the 7th ACCP guidelines).
We identified 685 validated thromboembolic events (643
schemic strokes and 42 peripheral emboli) that occurred off
linical Characteristics of Persons Witho valvular Atrial Fibrillation N t Tak ng Warfarint Baseline
Table 2
Clinical Characteristics of Persons With
Nonvalvular Atrial Fibrillation Not Taking Warfarin
at Baseline
Clinical Characteristic No. of Patients (%)
Age 75 yrs or older 5,026 (46.0)
Women 4,730 (43.3)
Prior ischemic stroke 909 (8.3)
Diagnosed hypertension 5,519 (50.5)
Diagnosed heart failure 3,143 (28.8)Diabetes mellitus 1,804 (16.5)
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February 26, 2008:810–5 Risk Stratification for AFarfarin therapy, for an overall rate of 2.1 per 100 person-
ears. The observed rates in all risk schemes increased
onotonically from low- to high-risk categories, but the
hromboembolic event rates in individual risk categories
aried across the risk stratification schemes (Fig. 1). The
roup of patients categorized as low risk using the 7th
CCP guidelines had an observed annualized thromboem-
olism rate of 0.13% (95% CI 0.05% to 0.32%). In com-
arison, the group of patients categorized as low risk using
he Framingham risk scheme had an observed thromboem-
olism rate of 0.81% (95% CI 0.66% to 0.99%). The
igh-risk patients of the 7th ACCP guidelines had an
bserved thromboembolism rate of 2.5% (95% CI 2.3% to
.7%), whereas the Framingham risk scheme high-risk
atients had an observed rate of 3.9% (95% CI 3.4% to
.5%).
All risk schemes had only a fair ability to separate patients
nto risk categories that corresponded to different rates of
roportion of ATRIA Cohort Categorized by 5 Risktratification Schemes Used to Predict Atrialibrilla –Related Thromboembolism andiscr m nat ry Ability f Risk Schemes (c-Statistics)
Table 3
Proportion of ATRIA Cohort Categorized by 5 Risk
Stratification Schemes Used to Predict Atrial
Fibrillation–Related Thromboembolism and
Discriminatory Ability of Risk Schemes (c-Statistics)
Risk for Thromboembolism (%) c-Statistic
Low Intermediate High All Patients Subgroup*
AFI 13.1 24.7 62.3 0.56 0.61
SPAF 27.7 28.5 43.8 0.60 0.65
CHADS2 18.8 61.2 20.1 0.58 0.67
Framingham 37.1 46.6 16.4 0.62 0.69
7th ACCP 11.7 7.9 80.4 0.56 0.60
Subgroup of 5,588 patients not on warfarin at baseline and with continuous follow-up off of
arfarin for at least 12 months.
Abbreviations as in Table 1.
Figure 1 Annual TE Rates Across Risk Groups Using 5 Risk
Stratification Schemes Used to Predict AF-Related TE
The double-barred lines represent 95% confidence intervals. ACCP  American
College of Chest Physicians Conference on Antithrombotic and Thrombolytic
Therapy; AF  atrial fibrillation; AFI  Atrial Fibrillation Investigators; CHADS2
 congestive heart failure, hypertension, age 75 years, diabetes mellitus,
and prior stroke or transient ischemic attack; SPAF  stroke prevention in
atrial fibrillation; TE  thromboembolism.lhromboembolism, which was reflected in c-statistics rang-
ng from 0.56 for the AFI and 7th ACCP risk schemes to
.62 for the Framingham risk scheme (Table 3). These
esults did not change materially in the subgroup analysis of
atients with continuous follow-up off warfarin for 12
onths (Table 3). Patients with and without thromboem-
olism had highly overlapping risk category distributions;
hese results are illustrated for the CHADS2 index in Figure
. As shown in Figure 3, all 5 risk schemes have roughly
omparable receiver-operating characteristic curves and dis-
riminating ability that is only moderately better than the
5° line of no information (12).
In additional sensitivity analyses, the c-statistic for the
ramingham score was essentially unchanged when the
iagnosis of hypertension was reassigned a point score of 2
r 4. A scoring system for the CHADS2 and Framingham
isk schemes that used their full range of possible values
esulted in only marginally better c-statistics than when
hree categories of risk were used: 0.60 using a continuous
core versus 0.58 using a 3-category score for the CHADS2
ndex, and 0.64 versus 0.62 for the Framingham score.
inally, restricting the analyses to primary prevention pa-
ients (i.e., those without a history of prior stroke) did not
hange our results materially.
iscussion
mong the 5 major risk stratification schemes commonly
sed to predict thromboembolism in patients with nonval-
ular AF, no one risk scheme seemed to be superior.
urthermore, all 5 schemes had at best only fair discrimi-
ating ability when applied to this cohort, with c-statistics
anging from 0.56 to 0.62, far from the ideal c-statistic
arget of 1. Although these risk categories were labeled as
Figure 2 Proportion of ATRIA Cohort Off Warfarin and Categorized
by CHADS2 Scores, Stratified by Development of TE
The distribution of person-years contributed by patients not sustaining a TE is
in blue and the distribution of person-years contributed by patients sustaining
a TE is in yellow. Abbreviations as in Figure 1.ow, intermediate, and high, the absolute rates of thrombo-
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Risk Stratification for AF February 26, 2008:810–5mbolism across these ordered categories increased by only
mall degrees. The 7th ACCP guideline’s categories of
ow-risk, intermediate-risk, and high-risk categories, for
xample, corresponded to absolute thromboembolism rates
f 0.13%, 0.89%, and 2.5% per year, only a modest revision
f the absolute risks. These low absolute event rates dictate
hat the majority of patients, even those predicted to be at
igh risk for thromboembolism, will not sustain a throm-
oembolic event. Better ways to predict thromboembolism
re clearly needed to optimize the use of anticoagulant
herapy in patients with AF, both to prevent the overuse of
nticoagulants in patients with low absolute risks of throm-
oembolism and to target the use of highly effective anti-
oagulant therapy to those patients who would most greatly
enefit.
Additional independent risk factors for AF–related
hromboembolism may not be included in current risk
chemes. Women, for example, seem to have a higher risk
or thromboembolism in the setting of atrial fibrillation
ndependent of other clinical risk factors (14). Other clinical
eatures and more novel biomarkers, including genetic
actors, may emerge as independent incremental risk factors
s well (15–17). However, it is unknown whether the
ncorporation of such risk factors will meaningfully improve
he discrimination of current risk schemes. In other situa-
ions, such as in predicting coronary events or stroke, the
ddition of new risk factors has resulted in only small
mprovements in the discriminatory ability of risk schemes
s compared with conventional risk factors alone (18–21).
uture validation studies are clearly needed to assess the
arginal utility of additional novel risk factors. Although
Figure 3 ROC Curves for 5 Risk Stratification Schemes
Used to Predict AF-Related Thromboembolism
The 45° dotted line represents the line of no information. ROC 
receiver-operating characteristic; other abbreviations as in Figure 1.here are concerns that the c-statistic is not an optimal aummary measure of the value of a prediction scheme (22),
-statistics in the range we observed clearly indicate rela-
ively poor discriminating ability.
Thromboembolic risk stratification for AF has some
hallenging features. Anticoagulant therapy is highly effec-
ive in reducing the risk of thromboembolism in AF.
ecause the consequences of ischemic stroke can be devas-
ating, treatment thresholds for anticoagulation can be set at
airly low absolute risks. Yet unlike many other cardiovas-
ular preventive therapies, warfarin is associated with po-
entially life-threatening complications, drug–drug interac-
ions, and burdensome monitoring and dose adjustment
23–25). This dilemma highlights the importance of im-
roving current methods of predicting thromboembolism. It
lso highlights the need for better ways to risk stratify
atients for major hemorrhage, in particular intracranial
emorrhage, which leads to most of the disability and death
rom warfarin toxicity (26).
There are several limitations to our study. The ATRIA
ohort lacked data on individual patients’ systolic blood
ressure and left ventricular systolic function. However,
ost applications of the widely cited CHADS2 index also
o not use such information, and in the original models of
he Framingham risk score, systolic blood pressure was not
ndependently statistically significant despite its being in-
orporated into the final risk scheme (8). The rates of
schemic stroke and other systemic embolism observed in
he ATRIA cohort are somewhat lower than those observed
n the early randomized trials and in cohorts assembled from
ospitalized patients with AF (2,7). The low thromboem-
olism rates observed in the ATRIA study may reflect the
act that our cohort was assembled primarily from ambula-
ory settings or perhaps because stroke risk factors were
etter managed in this more contemporary set of patients
27); other contemporary studies of patients with AF report
hromboembolism rates similar to the ATRIA study
28,29). Aspirin use was unavailable in our study because
onprescription aspirin would not be recorded in the pharmacy
atabase. Widespread aspirin use among nonanticoagulated
atients may have contributed to somewhat lower rates of
hromboembolism overall. The c-statistics reported in our
tudy are quite consistent with the results obtained from the
ooled trial populations and the Framingham cohort, and it is
nlikely that our study limitations materially affect the validity
f our core findings regarding the discriminating ability of
tandard risk schemes (8).
onclusions
urrent risk stratification schemes used to predict throm-
oembolism in persons with nonvalvular AF have similar
iscriminatory ability, but the ability is relatively poor. Until
etter means of risk stratification are available, a large
roportion of patients with AF who would not have
eveloped thromboembolism may be exposed to the risks
ssociated with warfarin therapy. In addition, differences
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February 26, 2008:810–5 Risk Stratification for AFcross risk schemes could potentially lead to substantial
ariation in whether or not individual patients are recom-
ended warfarin therapy. Further research is needed to
evelop more accurate ways to identify prospectively those
atients with AF who will sustain a thromboembolic event
ithout warfarin therapy, and similarly, robust methods are
eeded to identify reliably those patients who will suffer
omplications when treated with anticoagulants.
eprint requests and correspondence: Dr. Margaret C. Fang,
03 Parnassus Avenue, Box 0131, San Francisco, California
4143. E-mail: mfang@medicine.ucsf.edu.
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